Scarica l'app Stockscreener
180.77
1.38%
-2.53
Dopo l'orario di chiusura:
180.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$183.30
Aprire:
$184.18
Volume 24 ore:
150.25K
Relative Volume:
0.64
Capitalizzazione di mercato:
$3.54B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
72.02
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
-0.85%
1M Prestazione:
+8.74%
6M Prestazione:
+72.79%
1 anno Prestazione:
+68.69%
Intervallo 1D:
$178.34
$186.48
Intervallo di 1 settimana:
$177.35
$186.48
Portata 52W:
$93.58
$186.48
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Confronta LGND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
180.77 | 3.53B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Dec. 9, 2025: Ligand Investor Day — Harvard Club NYC, 10:30 a.m.–12:00 p.m. ET; live webcast & replay - Stock Titan
Combining price and volume data for Ligand Pharmaceuticals IncorporatedMarket Movement Recap & Smart Investment Allocation Tips - newser.com
Can technical indicators confirm Ligand Pharmaceuticals Incorporated’s reversal2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
Analyzing drawdowns of Ligand Pharmaceuticals Incorporated with statistical toolsMarket Activity Recap & Precise Swing Trade Entry Alerts - newser.com
Technical signs of recovery in Ligand Pharmaceuticals Incorporated2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Relative strength of Ligand Pharmaceuticals Incorporated in sector analysisJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
Is Ligand Pharmaceuticals Incorporated forming a reversal pattern2025 Sector Review & Risk Adjusted Buy and Sell Alerts - newser.com
Trend analysis for Ligand Pharmaceuticals Incorporated this weekJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Price action breakdown for Ligand Pharmaceuticals IncorporatedPortfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
Can Ligand Pharmaceuticals Incorporated stock sustain market leadershipDividend Hike & Reliable Trade Execution Plans - newser.com
Real time alert setup for Ligand Pharmaceuticals Incorporated performanceWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
Can Ligand Pharmaceuticals Incorporated stock deliver sustainable ROEEarnings Beat & Technical Pattern Alert System - newser.com
Published on: 2025-10-12 10:25:04 - newser.com
Ligand Pharmaceuticals (LGND): Evaluating Valuation After FDA Green Light for Lasix ONYU’s At-Home Heart Failure Solution - simplywall.st
Villere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Order flow analysis tools used on Ligand Pharmaceuticals IncorporatedPortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
How FDA Approval of Lasix ONYU Expands Ligand Pharmaceuticals' (LGND) Royalty Pipeline and Revenue Potential - simplywall.st
Ligand Pharmaceuticals Hits New 52-Week High of $186.40 - Markets Mojo
Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients - MarketScreener
Ligand (LGND) Gains FDA Approval for Lasix ONYU, Enhancing Heart Failure Treatment - GuruFocus
Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients - Quiver Quantitative
Ligand Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Ligand Partner SQ Innovation Receives FDA Approval for - GlobeNewswire
SQ Innovation Receives FDA Approval for Lasix ONYU | LGND Stock News - Stock Titan
Is Ligand Pharmaceuticals Incorporated (LGDN) stock bottoming after sell off2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Risk adjusted return profile for Ligand Pharmaceuticals Incorporated analyzedGlobal Markets & Short-Term High Return Ideas - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $184.26 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $183.81 - Markets Mojo
What analysts say about Ligand Pharmaceuticals Incorporated LGDN stockStock Rotation Strategies & Access Insider-Level Stock Analysis - earlytimes.in
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $183.98 By Investing.com - Investing.com Canada
Hot Picks: Three mid-cap stock picks poised for growth amid strong sector tailwinds - BNN Bloomberg
How to read the order book for Ligand Pharmaceuticals IncorporatedEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $181.62 - Markets Mojo
Press Release: Ligand Reports First Quarter 2025 Financial Results - 富途牛牛
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals Hits New 52-Week High at $177.77 - Markets Mojo
Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Price Target Increased by 410.53% to 0.05 - Nasdaq
Ligand Pharmaceuticals stock hits 52-week high at $172.49 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month HighWhat's Next? - MarketBeat
What drives Ligand Pharmaceuticals Incorporated LGDN stock priceBollinger Bands Signals & Affordable Stock Market Tips - earlytimes.in
What drives Ligand Pharmaceuticals Incorporated stock priceHead and Shoulders Patterns & Small Budget Capital Gains - Early Times
Ligand Pharmaceuticals Hits New 52-Week High of $170.78 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $172.45 - Markets Mojo
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):